Plain-English translation of NCT07217379 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing two experimental medications called and โ designed to help your immune system recognize and fight HIV โ in people living with HIV who are already on antiretroviral therapy. Researchers want to see if this treatment works better when combined with different approaches: continuing your regular HIV medications, briefly pausing treatment under close medical supervision, or adding a medication called that can activate hidden virus so your immune system can find it.
Even with effective HIV medications, the virus can hide in cells in a dormant state, meaning it's not actively replicating but it's still there. This trial exists to test whether the new immune therapy can help your body find and eliminate this hidden virus, potentially bringing people closer to a functional cure.
If you enroll, you'll be randomly assigned to one of three groups. All participants receive four infusions of the new medication spaced over 8โ10 weeks, given through an IV in a clinic setting. Depending on your group, you'll either continue your regular HIV medications throughout, briefly pause them for 8 weeks under close supervision, or take an additional oral medication alongside the infusions. You'll have regular blood tests to check your viral load, immune cell counts, and safety labs, and the study team will monitor you closely throughout the trial, which lasts several months.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
United States
Kenya